Next Science Ltd (NXS) AI Stock Analysis

• Market Cap: AU$42.43M
• Dividend Yield: N/A
• Average Volume (3M): 221.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: -4.27%
• EPS Growth: 33.91%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 292,625,370
• 10 Day Avg. Volume: 236,523
• 30 Day Avg. Volume: 221,575
• PEG Ratio: 0.04
• Price to Book (P/B): 6.03
• Price to Sales (P/S): 0.91
• P/FCF Ratio: -2.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$0.14 ▲(2.86% Upside)

Next Science Ltd's overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. While technical analysis indicates positive momentum, the valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Innovative Technology

The focus on innovative solutions for chronic wounds and biofilm infections positions Next Science as a leader in niche healthcare markets, potentially driving long-term growth through unique product offerings.

Proprietary Technology

The proprietary Xbio technology provides a competitive edge by disrupting biofilm, enhancing product efficacy, and potentially leading to increased market adoption and licensing opportunities.

Revenue Streams

Diverse revenue streams from direct sales and partnerships enhance market reach and stability, supporting sustainable growth and reducing dependency on single income sources.

Negative Factors

Profitability Challenges

Persistent profitability issues with negative margins indicate challenges in covering operational costs, which could hinder long-term financial health and investment capacity.

Negative Cash Flows

Ongoing negative cash flows suggest operational inefficiencies and potential liquidity issues, limiting the company's ability to invest in growth and innovation.

High Debt Levels

Moderate leverage with high debt levels and negative equity returns can strain financial flexibility, impacting the company's ability to fund future initiatives and manage economic downturns.

Next Science Ltd Business Overview & Revenue Model

Company Description

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.

How the Company Makes Money

Next Science generates revenue through the sale of its medical products, particularly those related to wound care and sinus health. The company markets its products directly to healthcare providers, hospitals, and clinics, leveraging both direct sales and distribution partnerships. Key revenue streams include product sales from its wound care line, which includes advanced dressings and topical solutions, as well as its sinus products aimed at addressing chronic sinusitis. Additionally, Next Science may engage in collaborations or partnerships with larger pharmaceutical companies, allowing for shared resources and expanded market reach, which can further enhance its earnings potential. The company also benefits from intellectual property rights associated with its proprietary technologies, which may provide licensing opportunities and contribute to its revenue.

Next Science Ltd Financial Statement Overview

Summary

Next Science Ltd is facing financial difficulties with persistent losses and negative cash flows. Despite modest revenue growth, the company struggles with severe profitability challenges, as indicated by negative margins and a strained balance sheet.

Income Statement

Next Science Ltd has experienced growth in revenue from 2023 to 2024, with a revenue growth rate of 2.87%. However, the company is facing significant challenges in profitability as indicated by negative EBIT and EBITDA margins. The net profit margin remains negative, highlighting ongoing losses and indicating the company is struggling to cover its operational costs.

Balance Sheet

The balance sheet reveals a strained financial position with a debt-to-equity ratio of 0.72, suggesting moderate leverage but reduced equity base. The return on equity is deeply negative at -307.61%, reflecting substantial losses relative to shareholder equity. The equity ratio stands at 37.37%, indicating a relatively balanced capital structure but a decline from previous years.

Cash Flow

Next Science Ltd's cash flow indicates operational challenges with negative operating and free cash flows. The free cash flow to net income ratio is negative, showing cash outflows persist. There is no positive cash flow growth, implying potential liquidity issues and limited cash generation capability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.82M	22.82M	22.18M	11.71M	8.95M	3.44M
Gross Profit	13.84M	18.44M	16.23M	11.90M	5.94M	2.47M
EBITDA	-6.17M	-9.03M	-14.42M	-12.25M	-9.22M	-11.83M
Net Income	-7.09M	-10.59M	-24.51M	-18.30M	-9.35M	-11.91M
Balance Sheet
Total Assets	9.46M	9.21M	17.90M	18.37M	13.67M	23.49M
Cash, Cash Equivalents and Short-Term Investments	971.24K	1.67M	9.28M	5.11M	7.35M	15.34M
Total Debt	5.30M	2.49M	961.97K	1.22M	275.19K	286.83K
Total Liabilities	10.02M	5.77M	5.08M	6.52M	2.94M	4.70M
Stockholders Equity	-557.03K	3.44M	12.82M	11.85M	10.73M	18.80M
Cash Flow
Free Cash Flow	-4.35M	-8.55M	-15.94M	-17.69M	-8.67M	-14.03M
Operating Cash Flow	-4.32M	-7.96M	-15.06M	-17.01M	-7.98M	-13.26M
Investing Cash Flow	-412.02K	-589.22K	-884.50K	-475.72K	-716.76K	-686.80K
Financing Cash Flow	2.12M	1.75M	20.11M	10.25M	1.43M	10.71M

Next Science Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.14
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NXS, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NXS.

Next Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$39.10M	10.93	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXS	48 Neutral	AU$42.43M	-2.91	-289.70%	―	-4.27%	33.91%
MVP	46 Neutral	AU$62.53M	545.00	0.19%	―	17.82%	―
IDT	37 Underperform	AU$20.97M	-2.68	-35.58%	―	45.30%	-24.18%

Next Science Ltd Corporate Events

Next Science Director Harry Thomas Hall IV Steps Down but Retains Shareholding

Next Science Limited has announced that director Harry Thomas Hall, IV (I.V. Hall) ceased to be a director of the company effective 31 December 2025. According to the final director’s interest notice lodged with the ASX, Hall retains a holding of 1,130,262 ordinary fully paid shares in the company, has no additional indirect holdings, and holds no interests in any related contracts, signalling a clean exit from board responsibilities while maintaining a substantial equity interest.

The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

ASX Suspends Next Science Shares Over Insufficient Operations

ASX has suspended Next Science Limited’s securities from quotation after determining that, six months after agreeing to dispose of its main undertaking, the company’s level of operations is no longer sufficient to warrant continued listing under ASX Listing Rule 12.1. The suspension will remain in place until ASX is satisfied that Next Science has rebuilt its operations to meet listing requirements, leaving shareholders unable to trade the stock in the meantime and underscoring regulatory pressure on companies that divest core assets without re-establishing an adequate operating base.

The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Sets Capital Return, Delisting Plan as CEO and CFO Resign

Next Science has called an extraordinary general meeting for 28 January 2026 to seek shareholder approval for an initial capital return of about A$0.145 per share, totalling roughly A$42.5 million, followed by the company’s removal from the ASX official list. Subject to shareholders endorsing the capital return and delisting, the board expects to convene a further meeting in February 2026 to propose a voluntary winding up and appointment of a liquidator, while CEO and managing director I.V. Hall and CFO Marc Zimmerman will step down on 31 December 2025 after the completion of the asset sale to OSARTIS, marking a decisive transition towards winding down the listed entity and returning value to shareholders.

The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Moves to Delist from ASX and Return Capital After Asset Sale

Next Science Limited has applied to be voluntarily removed from the ASX official list after completing the sale of substantially all of its assets to OSARTIS GmbH in September 2025, leaving the company without ongoing operations or plans for new business activity. The company plans to undertake an equal capital reduction to return most of the transaction proceeds to shareholders, retain a portion to cover the costs of the capital return, delisting, and an orderly voluntary winding up of the group, and then proceed to delist and commence liquidation, subject to shareholder approval at an extraordinary general meeting scheduled for 28 January 2026 and ASX consent, with an indicative delisting date of 13 February 2026. The board argues that ongoing listing, compliance and administrative costs would unnecessarily erode the final distribution to investors, and that delisting will maximise remaining value for shareholders as the company is effectively winding down rather than seeking new capital or growth opportunities.

The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Wins ASX Waiver to Enable Capital Return After Asset Sale

Next Science Limited has secured an ASX waiver from Listing Rule 7.25, allowing it to proceed with a planned capital return that may lower its share price below A$0.20, a critical step given the stock’s current trading range of A$0.055 to A$0.155. Following the completion of a US$50 million sale of substantially all of its assets to OSARTIS GmbH, the company intends to seek shareholder approval at an extraordinary general meeting in January 2026 for an interim capital return of surplus funds, a move that advances its wind-down process and would not have been possible without the waiver.

The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.